Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis

INTRODUCTION: The available oral anti-Xa agents are routinely used for the management of thrombotic disorders. A molecularly modified recombinant coagulation FXa, also known as Andexanet Alfa (AA), that has been developed as an antidote to neutralize the bleeding effects of oral FXa inhibitors, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehrotra, Siddharth, Hoppensteadt, Debra, Jeske, Walter, Siddiqui, Fakiha, Iqbal, Omer, Tafur, Alfonso, Lewis, Bruce, Jaradeh, Mark, Kantarcioglu, Bulent, Fareed, Jawed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742582/
https://www.ncbi.nlm.nih.gov/pubmed/36476125
http://dx.doi.org/10.1177/10760296221138297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742582/
https://www.ncbi.nlm.nih.gov/pubmed/36476125
http://dx.doi.org/10.1177/10760296221138297

Ejemplares similares